Current Report Filing (8-k)
January 10 2023 - 08:16AM
Edgar (US Regulatory)
0001551152 false Common Stock, $0.01 Par
Value ABBV 0001551152 2023-01-10 2023-01-10 0001551152
us-gaap:CommonStockMember exch:XNYS 2023-01-10 2023-01-10
0001551152 exch:XCHI us-gaap:CommonStockMember 2023-01-10
2023-01-10 0001551152 abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS 2023-01-10 2023-01-10 0001551152
abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2023-01-10
2023-01-10 0001551152 abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS 2023-01-10 2023-01-10 0001551152
abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2023-01-10
2023-01-10 0001551152 abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS 2023-01-10 2023-01-10 0001551152
abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2023-01-10
2023-01-10 0001551152 abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS 2023-01-10 2023-01-10 0001551152
abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2023-01-10
2023-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 10, 2023
ABBVIE INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1 North Waukegan Road
North Chicago,
Illinois
60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847)
932-7900
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange
Chicago Stock Exchange |
|
1.500% Senior Notes due 2023 |
|
ABBV23B |
|
New York Stock Exchange |
|
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
|
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
|
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
|
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
|
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
|
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
|
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
| Common Stock, $0.01 Par
Value |
ABBV |
Item 7.01 Regulation FD Disclosure
On January 10, 2023, AbbVie Inc. posted an investor
presentation to its website at:
https://investors.abbvie.com/presentations. A copy is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the
information in this Item 7.01 and Exhibit 99.1 incorporated
herein shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall they be deemed to be incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such a
filing. Additionally, the submission of the information set forth
in this Item 7.01 is not deemed an admission as to the materiality
of any information in this Current Report on Form 8-K that is
required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
ABBVIE
INC. |
| |
|
|
| Date: January 10, 2023 |
|
By: |
/s/ Scott T. Reents |
| |
|
|
Scott
T. Reents |
| |
|
|
Executive
Vice President, Chief Financial Officer |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2023 to Mar 2023
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2022 to Mar 2023
